Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person crizotinib-sensitive ALK mutants [cytosol]

Class:Id	DefinedSet:9700529
_displayName	crizotinib-sensitive ALK mutants [cytosol]
_timestamp	2023-10-12 19:27:25
compartment	[Compartment:70101] cytosol
created	[InstanceEdit:9700530] Rothfels, Karen, 2020-09-16
disease	[Disease:1500689] cancer
hasMember	[Complex:9700005] ALK F1174V dimer [plasma membrane] [Homo sapiens] [Complex:9701829] ALK L1198F dimer [plasma membrane] [Homo sapiens] [Complex:9713496] BCL11A(1-219)InsDHPPA-ALK(1058-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9713494] BIRC6(1-958)-ALK(1058-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9713509] EIF2AK3(30-144)-ALK(1058-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9699985] EML4(1-223)-ALK(1059-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9699976] EML4(1-223)insKMSTREKNSQV -ALK(1059-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9700022] EML4(1-486)-ALK(1058-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9713500] FN1(32-1201)-ALK(1022-1620) fusion dimer [plasma membrane] [Homo sapiens] [Complex:9712019] HIP1(1-1019)-ALK(1058-1620) dimer [cytosol] [Homo sapiens] [Complex:9712025] HIP1(1-963)-ALK(1058-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9712023] HIP1(1-719)InsL-ALK(1059-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9713504] PPM1B(2-282)-ALK(1058-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9713493] PRKAR1A(1-183)-ALK(1058-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9700523] STRN(1-137)-ALK(1058-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9699999] NPM1(1-117)-ALK(1058-1620) fusion dimer [cytosol] [Homo sapiens]
literatureReference	[LiteratureReference:9700343] Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK [LiteratureReference:9713378] Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer [LiteratureReference:9713340] BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib [LiteratureReference:9713415] Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization [LiteratureReference:9713357] Identification of a novel crizotinib-sensitive BCL11A-ALK gene fusion in a nonsmall cell lung cancer patient [LiteratureReference:9700357] Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma [LiteratureReference:9716593] Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity [LiteratureReference:9701767] EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors [LiteratureReference:9710786] RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer [LiteratureReference:9711845] Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib [LiteratureReference:9711777] HIP1-ALK, a novel ALK fusion variant that responds to crizotinib [LiteratureReference:9711859] HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma [LiteratureReference:9711850] Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer [LiteratureReference:9843025] IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma
modified	[InstanceEdit:9700562] Rothfels, Karen, 2020-09-16 [InstanceEdit:9713544] Rothfels, Karen, 2021-01-26 [InstanceEdit:9715308] Rothfels, Karen, 2021-02-17 [InstanceEdit:9716606] Rothfels, Karen, 2021-02-22 [InstanceEdit:9850948] Rothfels, Karen, 2023-10-12
name	crizotinib-sensitive ALK mutants
species	[Species:48887] Homo sapiens
stableIdentifier	[StableIdentifier:9700547] R-HSA-9700529.2
(hasMember)	[DefinedSet:9699981] type I TKI sensitive ALK mutants [plasma membrane] [Homo sapiens]
(updatedInstance)	[_UpdateTracker:9906356] Update Tracker - [DefinedSet:9700529] crizotinib-sensitive ALK mutants [cytosol] - v87:[addHasMember, addLiteratureReference]
[Change default viewing format]

No pathways have been reviewed or authored by crizotinib-sensitive ALK mutants [cytosol] (9700529)